Lenti-CD19 CAR (scFv-εRIγ, FMC63)-VP(VP-CAR-LC62)

The ready-to-use lentiviral particles of Lenti-CD19 CAR (scFv-εRIγ, FMC63)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. The target gene of scFv (FMC63)-FcεRIγ packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.

Specifications

Type of Therapeutics

Chimeric Antigen Receptor

Target

CD19

Expression Cassette

scFv (FMC63)-FcεRIγ

Clone

FMC63

Promotor

CMV

Packaging System

Lentivirus

Packaging Cell

293T

Targeting Diseases

Chronic lymphocytic leukemia (CLL)

Target

Introduction

Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. [provided by RefSeq, Jul 2008]

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.